Trials / Completed
CompletedNCT01814761
A Study of Bimatoprost 0.01% in the Clinical Setting
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 312 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of bimatoprost 0.01% (LUMIGAN® 0.01%) in subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who require further treatment for elevated intraocular pressure (IOP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimatoprost 0.01% | One drop of bimatoprost 0.01% (Lumigan® 0.01%) in the affected eye(s) every evening for 12 weeks. |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2013-03-20
- Last updated
- 2015-10-26
- Results posted
- 2015-10-26
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT01814761. Inclusion in this directory is not an endorsement.